컨텐츠 내용을 수정할 수 있습니다
Reversal agents work in one of four ways:
| Mechanism | Example |
|---|---|
| Binds the drug directly and neutralizes it | Protamine (positively charged, binds negatively charged heparin); idarucizumab (antibody fragment that binds dabigatran); digoxin immune Fab (binds digoxin) |
| Replaces what the drug removed | Vitamin K lets the liver make active factors II, VII, IX, and X again; prothrombin complex concentrate (PCC) supplies those factors immediately; plasma supplies all factors |
| Blocks the receptor | Naloxone (opioid receptor), flumazenil (benzodiazepine site), atropine (muscarinic receptor) |
| Blocks toxic metabolism or restores an enzyme | Fomepizole (alcohol dehydrogenase), acetylcysteine (glutathione), pralidoxime (acetylcholinesterase), methylene blue (reduces methemoglobin) |
Timing matters: vitamin K takes hours, so it is paired with PCC for serious bleeding; protamine only reverses heparin still in the blood (UFH half-life about 1–2 hours).
| Anticoagulant | Reversal | Key point |
|---|---|---|
| Unfractionated heparin (IV) | Protamine sulfate — about 1 mg per 100 units of heparin given in the previous 2–3 hours; maximum 50 mg per dose; slow IV | Monitor aPTT or anti-Xa after |
| LMWH (enoxaparin) | Protamine (1 mg per 1 mg enoxaparin within 8 hours) — partial reversal only | Anti-Xa activity only about 60% neutralized |
| Warfarin — major or life-threatening bleeding | 4-factor PCC + vitamin K 5–10 mg by slow IV infusion | Plasma if PCC unavailable (larger volume, slower) |
| Warfarin — INR high, no bleeding | INR above range but below 4.5: hold or lower dose. INR 4.5–10: hold doses; routine vitamin K not recommended. INR above 10: hold and give oral vitamin K (e.g., 2.5–5 mg) | Recheck INR in 24 hours |
| Dabigatran | Idarucizumab 5 g IV (two 2.5 g vials) | Dabigatran is also removed by hemodialysis |
| Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) | 4-factor PCC in the US | Andexanet alfa was withdrawn from the US market in December 2025; availability elsewhere may differ |
| Thrombolytics (alteplase, tenecteplase) | Stop infusion; cryoprecipitate (fibrinogen); tranexamic acid or aminocaproic acid | Neuro checks — intracranial hemorrhage |
For every anticoagulant: also give local pressure, blood products as needed, and activated charcoal for a recent oral overdose if the airway is safe.
| Poison | Antidote | Key points |
|---|---|---|
| Digoxin | Digoxin immune Fab | Vials ≈ (serum digoxin in ng/mL × weight in kg) ÷ 100, or empiric vials for acute ingestion; potassium falls after Fab |
| Acetaminophen | Acetylcysteine | See Topic 62 |
| Opioids | Naloxone | Titrate to breathing |
| Benzodiazepines | Flumazenil | Seizure risk |
| Organophosphates | Atropine, pralidoxime | Titrate to dry secretions |
| Beta blockers / CCBs | Glucagon, calcium, high-dose insulin | See Topic 63 |
| Methanol, ethylene glycol | Fomepizole | Plus dialysis |
| Cyanide | Hydroxocobalamin | Red skin and urine |
| Iron | Deferoxamine IV | For severe poisoning (shock, acidosis, altered mental status, or serum iron above about 500 mcg/dL [90 µmol/L]); "vin rosé" (reddish) urine |
| Methemoglobinemia (dapsone, nitrates, benzocaine and other topical anesthetics) | Methylene blue 1–2 mg/kg IV over 5 minutes | Chocolate-brown blood; SpO₂ reads about 85% |
| Anticholinergic delirium | Physostigmine (selected, pure anticholinergic cases) | Not in tricyclic overdose |
| Sulfonylureas | Dextrose + octreotide | Octreotide prevents rebound hypoglycemia |
| Isoniazid (seizures) | Pyridoxine | Seizures resist usual drugs |
| Tricyclic antidepressants | Sodium bicarbonate | QRS > 100 ms |
| Local anesthetic systemic toxicity | 20% lipid emulsion | Bolus about 1.5 mL/kg, then infusion |
| Malignant hyperthermia | Dantrolene 2.5 mg/kg IV | Sterile water diluent |
| Serotonin syndrome | Cyproheptadine (plus benzodiazepines, cooling) | Oral or by NG tube only |
| Magnesium toxicity | Calcium gluconate | 10 mL of 10% IV over about 3 minutes |
| Methotrexate | Leucovorin (folinic acid); glucarpidase | Leucovorin rescue on schedule |
| Rocuronium, vecuronium | Sugammadex | Backup contraception for 7 days |
| Lead | Chelation (succimer, edetate calcium disodium) | Remove the source; never confuse with edetate disodium (fatal hypocalcemia) |
| Drug | Key adverse effects |
|---|---|
| Protamine | Boxed warning: hypotension, cardiovascular collapse, anaphylaxis, pulmonary hypertension, bradycardia — especially with fast injection; excess protamine itself prolongs clotting |
| Vitamin K (phytonadione) IV | Boxed warning: severe hypersensitivity reactions, including fatal anaphylaxis, with IV or IM use — IV only when needed, diluted and infused slowly; SC absorption is unreliable and IM causes hematoma in coagulopathy |
| 4-factor PCC | Boxed warning: arterial and venous thrombosis (stroke, MI, PE); contains heparin in some products |
| Plasma | Volume overload (TACO), TRALI, allergic reactions; needs thawing and ABO matching |
| Idarucizumab | Thromboembolism once anticoagulation is removed; headache; hypokalemia |
| Digoxin immune Fab | Hypokalemia, worsening HF, rapid ventricular rate in atrial fibrillation, allergic reaction |
| Deferoxamine | Hypotension with rapid infusion; ARDS with prolonged infusion (beyond about 24 hours) |
| Methylene blue | Blue-green urine and skin; boxed warning: serotonin syndrome with serotonergic drugs; hemolysis in G6PD deficiency |
| Physostigmine | Bradycardia, asystole, seizures, bronchorrhea |
Listed in priority order.
| Problem | Findings | Management |
|---|---|---|
| Heparin overdose | Bleeding, prolonged aPTT | Stop infusion; protamine |
| Warfarin excess | High INR ± bleeding | Hold; oral vitamin K if INR above 10; 4F-PCC + IV vitamin K for major bleeding |
| Superwarfarin rodenticide (brodifacoum) | Prolonged, severe coagulopathy | Vitamin K for weeks to months; PCC or plasma for bleeding |
| DOAC excess | Bleeding | Idarucizumab (dabigatran); 4F-PCC (factor Xa inhibitors, US) |
| Protamine excess or reaction | Hypotension, bronchospasm, bleeding | Stop; epinephrine for anaphylaxis; supportive |
| Reversal-related thrombosis | Stroke, MI, DVT/PE after PCC or idarucizumab | Report new symptoms at once |
| Digoxin toxicity | Dysrhythmias, hyperkalemia | Digoxin immune Fab; potassium monitoring |
| Iron overdose | Vomiting, GI bleeding, then latent phase, then shock, acidosis, liver failure | Deferoxamine; whole-bowel irrigation |
다음 이론을 계속 학습하려면 로그인하세요.
로그인하고 계속 학습필기노트, 하이라이터, 메모는 잘 쓰고 있어?
내보내줘운영진이 검토할게요!
마이페이지에서 차단한 회원을 관리할 수 있어요.